CHARM: COVID-19 Health Action Response for Marines-Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 30 12 2021
accepted: 24 03 2022
entrez: 7 4 2022
pubmed: 8 4 2022
medline: 15 4 2022
Statut: epublish

Résumé

SARS-CoV-2 T cell responses are associated with COVID-19 recovery, and Class I- and Class II-restricted epitopes have been identified in the spike (S), nucleocapsid (N) and membrane (M) proteins and others. This prospective COVID-19 Health Action Response for Marines (CHARM) study enabled assessment of T cell responses against S, N and M proteins in symptomatic and asymptomatic SARS-CoV-2 infected participants. At enrollment all participants were negative by qPCR; follow-up occurred biweekly and bimonthly for the next 6 weeks. Study participants who tested positive by qPCR SARS-CoV-2 test were enrolled in an immune response sub-study. FluoroSpot interferon-gamma (IFN-γ) and IL2 responses following qPCR-confirmed infection at enrollment (day 0), day 7 and 14 and more than 28 days later were measured using pools of 17mer peptides covering S, N, and M proteins, or CD4+CD8 peptide pools containing predicted epitopes from multiple SARS-CoV-2 antigens. Among 124 asymptomatic and 105 symptomatic participants, SARS-CoV-2 infection generated IFN-γ responses to the S, N and M proteins that persisted longer in asymptomatic cases. IFN-γ responses were significantly (p = 0.001) more frequent to the N pool (51.4%) than the M pool (18.9%) among asymptomatic but not symptomatic subjects. Asymptomatic IFN-γ responders to the CD4+CD8 pool responded more frequently to the S pool (55.6%) and N pool (57.1%), than the M pool (7.1%), but not symptomatic participants. The frequencies of IFN-γ responses to the S and N+M pools peaked 7 days after the positive qPCR test among asymptomatic (S pool: 22.2%; N+M pool: 28.7%) and symptomatic (S pool: 15.3%; N+M pool 21.9%) participants and dropped by >28 days. Magnitudes of post-infection IFN-γ and IL2 responses to the N+M pool were significantly correlated with IFN-γ and IL2 responses to the N and M pools. These data further support the central role of Th1-biased cell mediated immunity IFN-γ and IL2 responses, particularly to the N protein, in controlling COVID-19 symptoms, and justify T cell-based COVID-19 vaccines that include the N and S proteins.

Identifiants

pubmed: 35390102
doi: 10.1371/journal.pone.0266691
pii: PONE-D-21-41021
pmc: PMC8989306
doi:

Substances chimiques

Antibodies, Viral 0
COVID-19 Vaccines 0
Epitopes 0
Interleukin-2 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0266691

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
PLoS One. 2021 Aug 20;16(8):e0256396
pubmed: 34415964
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
Cell Host Microbe. 2020 Apr 8;27(4):671-680.e2
pubmed: 32183941
JCI Insight. 2017 Jan 12;2(1):e89154
pubmed: 28097230
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
Clin Microbiol Infect. 2021 Jul;27(7):1029-1034
pubmed: 33813122
Cell Host Microbe. 2021 Jul 14;29(7):1124-1136.e11
pubmed: 34171266
J Virol. 2020 Jun 16;94(13):
pubmed: 32546606
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nat Med. 2021 Feb;27(2):270-278
pubmed: 33335323
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
N Engl J Med. 2020 Dec 17;383(25):2407-2416
pubmed: 33176093
Sci Immunol. 2021 Mar 4;6(57):
pubmed: 33664060
PLoS One. 2013;8(2):e55571
pubmed: 23457473
Clin Microbiol Infect. 2021 Dec;27(12):1784-1789
pubmed: 34256141
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Cell Rep. 2021 Jul 20;36(3):109414
pubmed: 34260965
Front Microbiol. 2020 Jul 22;11:1800
pubmed: 32793182
Cell Discov. 2021 Mar 25;7(1):18
pubmed: 33767156
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
PLoS One. 2021 Jan 25;16(1):e0245532
pubmed: 33493185
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Sci Transl Med. 2021 Apr 21;13(590):
pubmed: 33723016
J Med Virol. 2022 Apr;94(4):1728-1733
pubmed: 34897752
PLoS One. 2021 Sep 8;16(9):e0256980
pubmed: 34495988
Nat Immunol. 2021 Jan;22(1):74-85
pubmed: 32999467
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Med. 2021 Mar 12;2(3):281-295.e4
pubmed: 33589885
Science. 2021 Apr 30;:
pubmed: 33931567
JCI Insight. 2020 Oct 15;5(20):
pubmed: 32937615
J Clin Invest. 2021 Nov 1;131(21):
pubmed: 34720095
Immunity. 2021 May 11;54(5):1055-1065.e5
pubmed: 33945786
iScience. 2021 Feb 19;24(2):102096
pubmed: 33521593
Comput Struct Biotechnol J. 2021;19:518-529
pubmed: 33398234
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Nucleic Acids Res. 2020 Jul 2;48(W1):W449-W454
pubmed: 32406916
J Infect. 2020 Jul;81(1):e51-e60
pubmed: 32315725
Front Cell Infect Microbiol. 2020 Dec 18;10:605334
pubmed: 33392109
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
EBioMedicine. 2021 Jun;68:103401
pubmed: 34051441
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Nat Immunol. 2021 May;22(5):620-626
pubmed: 33674800
J Immunol. 2021 Jul 15;207(2):376-379
pubmed: 34193597
Bioinformatics. 2016 Feb 15;32(4):511-7
pubmed: 26515819
Cell Rep. 2021 Jul 20;36(3):109415
pubmed: 34270919
Nat Immunol. 2022 Jan;23(1):50-61
pubmed: 34853448
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
NPJ Vaccines. 2021 May 13;6(1):74
pubmed: 33986272
Lancet Respir Med. 2021 Jul;9(7):712-720
pubmed: 33865504
PLoS One. 2014 Sep 11;9(9):e106241
pubmed: 25211344
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
J Exp Med. 2021 May 3;218(5):
pubmed: 33646265
Sci Adv. 2021 May 28;7(22):
pubmed: 34049881
Cell Rep. 2021 Sep 14;36(11):109708
pubmed: 34506741
J Clin Invest. 2020 Sep 1;130(9):4694-4703
pubmed: 32463803
Front Immunol. 2020 Oct 28;11:587615
pubmed: 33193414
J Immunol. 2017 Nov 1;199(9):3360-3368
pubmed: 28978689
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
bioRxiv. 2021 Mar 01;:
pubmed: 33688655
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Science. 2021 Mar 25;:
pubmed: 33766944
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Immunogenetics. 2013 Oct;65(10):711-24
pubmed: 23900783
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Vaccines (Basel). 2020 Jul 23;8(3):
pubmed: 32717854
Cell Host Microbe. 2021 Jul 14;29(7):1076-1092
pubmed: 34237248
Adv Drug Deliv Rev. 2021 Apr;171:29-47
pubmed: 33465451
Nat Immunol. 2020 Sep;21(9):1107-1118
pubmed: 32788748

Auteurs

Martha Sedegah (M)

Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.

Chad Porter (C)

Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.

Michael R Hollingdale (MR)

Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation, Bethesda, MD, United States of America.

Harini Ganeshan (H)

Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation, Bethesda, MD, United States of America.

Jun Huang (J)

Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation, Bethesda, MD, United States of America.

Carl W Goforth (CW)

Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.

Maria Belmonte (M)

Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation, Bethesda, MD, United States of America.

Arnel Belmonte (A)

Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
GDIT, MD, United States of America.

Dawn L Weir (DL)

Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.

Rhonda A Lizewski (RA)

U.S. Naval Medical Research Unit SIX, Lima, Perú.

Stephen E Lizewski (SE)

U.S. Naval Medical Research Unit SIX, Lima, Perú.

Stuart C Sealfon (SC)

Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.

Vihasi Jani (V)

Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
Henry M. Jackson Foundation, Bethesda, MD, United States of America.

Ying Cheng (Y)

Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
Leidos, Reston, VA, United States of America.

Sandra Inoue (S)

Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
GDIT, MD, United States of America.

Rachael Velasco (R)

Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.

Eileen Villasante (E)

Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.

Peifang Sun (P)

Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.

Andrew G Letizia (AG)

Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH